◎ Sugi Atlas

Atlas / Drug / Clobetasol Propionate

Clobetasol Propionate

drug
On this page

Also known as CCI 4725CCI-4725ClareluxClobadermClobecort amexClobetasolClobetasol propionate (emollient)ClobexCormaxDermovateDermovate nnDovateEmbelineEmbeline eEtrivexGR 2/925GR-2/925ImpekloImpoyz

Summary

Clobetasol Propionate (CHEMBL1159650) is an approved small-molecule anti-inflammatory drug (ATC D07AD01) targeting NR3C1; indicated across 17 conditions including psoriasis and skin disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: D07AD01
  • Targets: 1 (NR3C1)
  • Indications: 17 conditions
  • Clinical trials: 70
  • Chemistry: 467 Da · C25H32ClFO5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1159650
NameClobetasol Propionate
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID32798
ChEBICHEBI:31414
ATCD07AD01
Molecular formulaC25H32ClFO5
Molecular weight467
InChIKeyCBGUOGMQLZIXBE-XGQKBEPLSA-N

SMILES: CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl

IUPAC name: [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate

ChEBI definition: The 17-O-propionate ester of clobetasol. A potent corticosteroid, it is used to treat various skin disorders, including exzema and psoriasis.

Pharmacological roles (ChEBI): anti-inflammatory drug.

Also known as: CCI 4725, CCI-4725, Clarelux, Clobaderm, Clobecort amex, Clobetasol, Clobetasol propionate, Clobetasol propionate (emollient), Clobex, Cormax, Dermovate, Dermovate nn

Patent coverage: 8,190 distinct patent families (30,865 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
NR3C1Glucocorticoid receptorAgonist9.180.9%P04150

Broader ChEMBL bioactivity targets: 18 (assay-derived). Sample: Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Survival motor neuron protein, Prelamin-A/C, Beta-lactamase, Glucocorticoid receptor, Bile salt export pump, Progesterone receptor, Motilin receptor, Peroxisome proliferator-activated receptor gamma.

Bioactivity

ChEMBL activities: 22 potent at pChembl ≥ 5 of 37 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
NR3C19.18Ki0.66nMCHEMBL_ACT_7693085
NR3C18.84IC501.46nMCHEMBL_ACT_7693084
CYP3A58.7IC502nMCHEMBL_ACT_29156691
P065368.5IC503.17nMCHEMBL_ACT_935741
NR3C18.11AC507.8nMCHEMBL_ACT_25175974
CYP3A57.68IC5021nMCHEMBL_ACT_18931032
CYP3A57.36IC5044nMCHEMBL_ACT_18931028
PGR7.28AC5053nMCHEMBL_ACT_25223140
CYP3A57.11IC5078nMCHEMBL_ACT_18931030
CYP3A57Kd100nMCHEMBL_ACT_18931059
CYP3A56.99IC50103nMCHEMBL_ACT_18931034
CYP3A46.69IC50206nMCHEMBL_ACT_18931013
NPSR16Potency1000nMCHEMBL_ACT_3607519
NPSR16Potency1000nMCHEMBL_ACT_5045391
NR1I25.82AC501500nMCHEMBL_ACT_25224401
SMN15.8Potency1585nMCHEMBL_ACT_3870499
NPSR15.7Potency1995nMCHEMBL_ACT_4932487
P152075.6Ki2517nMCHEMBL_ACT_7695266
P152075.42IC503775nMCHEMBL_ACT_7695265
NR1I25.29AC505100nMCHEMBL_ACT_25188273
ABCB115.07IC508500nMCHEMBL_ACT_15460386
ABCB115.07IC508500nMCHEMBL_ACT_18051997

Target pathways

Aggregated over 1 target gene(s): NR3C1.

Top Reactome pathways

8 total, by targets touching each:

PathwayTargetsGenes
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand1NR3C1
Nuclear Receptor transcription pathway1NR3C1
SUMOylation of intracellular receptors1NR3C1
PTK6 Expression1NR3C1
Regulation of RUNX2 expression and activity1NR3C1
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes1NR3C1
Potential therapeutics for SARS1NR3C1
Regulation of NPAS4 gene transcription1NR3C1

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II1
regulation of gluconeogenesis1
chromatin organization1
regulation of DNA-templated transcription1
regulation of transcription by RNA polymerase II1
apoptotic process1
chromosome segregation1
signal transduction1
glucocorticoid metabolic process1
response to wounding1
gene expression1
microglia differentiation1
adrenal gland development1
nuclear receptor-mediated steroid hormone signaling pathway1
regulation of glucocorticoid biosynthetic process1

Indications & clinical

Indications

17 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
psoriasis4MONDO:0005083EFO:0000676
skin disorder4MONDO:0005093EFO:0000701
alopecia areata3MONDO:0005340EFO:0004192
seborrheic dermatitis3MONDO:0006608EFO:1000764
bullous pemphigoid3MONDO:0019082EFO:0007187
vulvar lichen sclerosus3MONDO:0006491EFO:1000623
lichen disease3MONDO:0006570EFO:1000724
rheumatoid arthritis3MONDO:0008383EFO:0000685
cataract3MONDO:0005129MONDO:0005129
lichen planus2MONDO:0006572EFO:1000726
lichen planus, oral2MONDO:0043923EFO:0008517
rectal cancer2MONDO:0006519EFO:1000657
colon adenocarcinoma2MONDO:0002271EFO:1001949
colorectal adenocarcinoma2MONDO:0005008EFO:0000365
colorectal carcinoma2MONDO:0024331EFO:1001951
atopic eczema1MONDO:0004980EFO:0000274

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 70.

Phase distribution

PhaseTrials
PHASE216
PHASE415
Not specified12
PHASE310
PHASE110
PHASE2/PHASE33
PHASE1/PHASE23
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00436540PHASE4COMPLETEDA Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam
NCT00437255PHASE4COMPLETEDEfficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
NCT00779792PHASE4UNKNOWNEfficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation
NCT00828464PHASE4COMPLETEDStudy to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis
NCT00852761PHASE4COMPLETEDA Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis
NCT01012713PHASE4COMPLETEDSafety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis
NCT01111981PHASE4UNKNOWNSafety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia
NCT01205880PHASE4COMPLETEDStudy to Evaluate Vectical in Combination With Clobex Spray to Treatment Plaque Psoriasis
NCT01323673PHASE4COMPLETEDEthanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.
NCT01745133PHASE4COMPLETEDOlux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
NCT01893567PHASE4COMPLETEDSubject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
NCT03453190PHASE4UNKNOWNApremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis
NCT03535233PHASE4COMPLETEDTopical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata
NCT03926377PHASE4UNKNOWNInfluence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid
NCT04951206PHASE4COMPLETEDFractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus
NCT04364555PHASE2/PHASE3ACTIVE_NOT_RECRUITINGEfficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.
NCT05724446PHASE3RECRUITINGClobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
NCT00715975PHASE2/PHASE3COMPLETEDEffectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis
NCT01282515PHASE2/PHASE3COMPLETEDTreatment of Female Genital Erosive Lichen Planus(GELP) With Hexaminolevulinate PDT
NCT01453686PHASE3COMPLETEDA Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata
NCT01699412PHASE3COMPLETEDClinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease
NCT02313870PHASE3COMPLETEDTopical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid
NCT02573883PHASE3COMPLETEDClobetasol Propionate Versus Fractionated Carbon Dioxide Laser for the Treatment of Lichen Sclerosus
NCT04246801PHASE3COMPLETEDClobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
NCT04249076PHASE3COMPLETEDClobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
NCT04649697PHASE3UNKNOWNRebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients
NCT05010421PHASE3COMPLETEDLaser vs Clobetasol for Lichen Sclerosus
NCT05364515PHASE3WITHDRAWNPlasma Rich in Growth Factors (PRGF) for the Treatment of Lichen Sclerosus Atrophicus of the Vulva
NCT06120140PHASE2ACTIVE_NOT_RECRUITINGEnhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06742333PHASE2RECRUITINGEarly Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
NCT07100613PHASE2RECRUITINGMucoadhesive Modified-Release Formulations for the Topical Treatment of Symptomatic Oral Lichen Planus
NCT00393263PHASE2COMPLETEDClobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus
NCT00757874PHASE2COMPLETEDTacrolimus Versus Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus
NCT01126255PHASE2TERMINATEDProgesterone vs Clobetasol Propionate in Vulvar Lichen Sclerosus
NCT01407471PHASE2COMPLETEDInterest of Topical Spironolactone’s Administration to Prevent Corticoid-induced Epidermal Atrophy
NCT01557517PHASE2COMPLETEDClobetasol for Oral Graft-Versus-Host Disease
NCT02319616PHASE1/PHASE2WITHDRAWNTopical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
NCT02368886PHASE2COMPLETEDLower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT02744378PHASE2COMPLETEDComparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus
NCT03026478PHASE2UNKNOWNTopical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

173 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FULVESTRANTChEMBL + PubChemPhase 4 (approved)NR3C1
PODOFILOXChEMBL + PubChemPhase 4 (approved)NR3C1
REGORAFENIBChEMBL + PubChemPhase 4 (approved)NR3C1
ACENOCOUMAROLChEMBLPhase 4 (approved)NR3C1
ALCLOMETASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
AMCINONIDEChEMBLPhase 4 (approved)NR3C1
AMIODARONEChEMBLPhase 4 (approved)NR3C1
APREPITANTChEMBLPhase 4 (approved)NR3C1
AURANOFINChEMBLPhase 4 (approved)NR3C1
BAZEDOXIFENEChEMBLPhase 4 (approved)NR3C1
BECLOMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BENZBROMARONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE DIPROPIONATEChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE PHOSPHORIC ACIDChEMBLPhase 4 (approved)NR3C1
BETAMETHASONE VALERATEChEMBLPhase 4 (approved)NR3C1
BUDESONIDEChEMBLPhase 4 (approved)NR3C1
BUTOCONAZOLEChEMBLPhase 4 (approved)NR3C1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)NR3C1
CANRENONEChEMBLPhase 4 (approved)NR3C1
CHLORMADINONEChEMBLPhase 4 (approved)NR3C1
CICLESONIDEChEMBLPhase 4 (approved)NR3C1
CLOFAZIMINEChEMBLPhase 4 (approved)NR3C1
CLOTRIMAZOLEChEMBLPhase 4 (approved)NR3C1
CORTISONEChEMBLPhase 4 (approved)NR3C1
DANAZOLChEMBLPhase 4 (approved)NR3C1
DAUNORUBICINChEMBLPhase 4 (approved)NR3C1
DEFLAZACORTChEMBLPhase 4 (approved)NR3C1
DESOGESTRELChEMBLPhase 4 (approved)NR3C1
DESONIDEChEMBLPhase 4 (approved)NR3C1
DESOXIMETASONEChEMBLPhase 4 (approved)NR3C1
DESOXYCORTICOSTERONE PIVALATEChEMBLPhase 4 (approved)NR3C1
DEXAMETHASONEChEMBLPhase 4 (approved)NR3C1
DEXTROTHYROXINEChEMBLPhase 4 (approved)NR3C1
DIENESTROLChEMBLPhase 4 (approved)NR3C1
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)NR3C1
DIFLORASONE DIACETATEChEMBLPhase 4 (approved)NR3C1
DOXORUBICINChEMBLPhase 4 (approved)NR3C1
DROSPIRENONEChEMBLPhase 4 (approved)NR3C1
ECONAZOLEChEMBLPhase 4 (approved)NR3C1
EFAVIRENZChEMBLPhase 4 (approved)NR3C1
ENZALUTAMIDEChEMBLPhase 4 (approved)NR3C1
EPLERENONEChEMBLPhase 4 (approved)NR3C1
ESTRADIOLChEMBLPhase 4 (approved)NR3C1
ESTRIOLChEMBLPhase 4 (approved)NR3C1
ETHINYL ESTRADIOLChEMBLPhase 4 (approved)NR3C1
EXEMESTANEChEMBLPhase 4 (approved)NR3C1
FELODIPINEChEMBLPhase 4 (approved)NR3C1
FLUDROCORTISONEChEMBLPhase 4 (approved)NR3C1
FLUNISOLIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINOLONE ACETONIDEChEMBLPhase 4 (approved)NR3C1
FLUOCINONIDEChEMBLPhase 4 (approved)NR3C1
FLUOROMETHOLONEChEMBLPhase 4 (approved)NR3C1
FLUOXYMESTERONEChEMBLPhase 4 (approved)NR3C1
FLURANDRENOLIDEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE FUROATEChEMBLPhase 4 (approved)NR3C1
FLUTICASONE PROPIONATEChEMBLPhase 4 (approved)NR3C1
GLUCAGONChEMBLPhase 4 (approved)NR3C1
HALCINONIDEChEMBLPhase 4 (approved)NR3C1
HYDROCORTISONEChEMBLPhase 4 (approved)NR3C1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot